

Good tolerability when switching from an aqueous ultra-rush Hymenoptera venom immunotherapy to a depot preparation

To the Editor,

Throughout Europe, aqueous preparations are generally used for the rapid up-dosing phase of Hymenoptera venom allergen immunotherapy (VIT) and are often substituted with an aluminum adsorbed (so-called "depot") preparation during maintenance treatment.¹ While VIT tolerability has been widely investigated,^{2,3} only a few previous studies have included data on patients' tolerance of switching from an aqueous to a depot preparation.^{4,5} The question of the interchangeability of venom preparations has been recently pointed out.⁶ For the cohort of 90 patients, we studied previously that no systemic reactions occurred when an aqueous preparation was substituted with a depot preparation with vespid VIT.⁷ In the current study, we evaluated the tolerability in over 200 more patients to both vespid and bee VIT when an aqueous preparation was substituted with a "purified" depot extract from a different manufacturer.

For inpatient up-dosing of VIT at the Division of Allergy and Immunology, subcutaneous injections of the aqueous venom extract VenomilTM (Bencard Allergie GmbH) are administered according to a 3-day ultra-rush protocol.⁸ For maintenance, the preparation is switched to the ALK-depot SQTM (ALK-Abelló Arzneimittel GmbH). Patient records were reviewed to locate those who underwent vespid (200 patients) or bee (20 patients) VIT between 2003 and 2018. Patient characteristics before VIT initiation are presented in Table 1. The mean duration of the vespid or bee VIT was 3 years. Systemic allergic reactions during the buildup phase, after the first injection of the depot preparation, and during the maintenance phase of vespid and bee VIT were classified according to the World Allergy Organization (WAO) grading system for allergen immunotherapy systemic allergic reactions (Figure 1).

Eight of the 200 patients (4%) receiving vespid VIT had systemic allergic reactions during the up-dosing phase, with WAO grade 1 reactions occurring in six patients (3%) and WAO grade 2 reactions occurring in 2 (1%). These reactions were mostly cutaneous and gastrointestinal, including pruritus, urticaria, flushing, angioedema, nausea, headache, and abdominal cramps. No respiratory or cardiovascular symptoms were observed. After the first injection of the depot preparation during the maintenance phase, three patients (1.5%) had allergic reactions, 2 of which were WAO grade 1 (1%) with generalized pruritus and 1 of which was WAO grade 2 (0.5%)

with abdominal cramps. During subsequent injections of the maintenance dose using a depot preparation, nine patients (4.5%) had allergic reactions, with WAO grade 1 reactions occurring in five patients (2.5%) and WAO grade 2 reactions occurring in 4 (2%). The allergic reactions were pruritus, angioedema, rhinitis, cough, nausea, headache, abdominal cramps, and diarrhea. Three of the 20 patients (15%) undergoing bee VIT experienced allergic reactions during the up-dosing phase, with 2 who had WAO grade 1 (10%) and 1 who had WAO grade 2 reactions (5%). Symptoms included pruritus, urticaria, itchy throat, and cough. Switching from the aqueous to the depot preparation was well tolerated in all patients, and no systemic allergic reactions were documented with the first injection of the depot preparation. During the following injections of the maintenance dose, one patient (5%) had a WAO grade 1 allergic reaction with generalized pruritus. No systemic allergic reactions occurred in the four cohort patients who received both vespid and bee VIT in the up-dosing, when the switch occurred, nor during the maintenance phase. Moreover, in this cohort, systemic allergic reactions occurred only once during VIT and did not occur twice in the same patient.


The main risk factor for allergic reactions during VIT is treatment with bee venom. Significantly higher rates of systemic reactions after bee VIT compared to vespid VIT have been consistently reported.^{2,3} Our data show similar findings, with a higher number of allergic reactions occurring during the up-dosing phase of bee VIT compared to vespid VIT. However, the large difference in the number of total patients undergoing bee and vespid VIT in our study (ie, 20 vs 200) must be taken into account. Other risk factors for allergic reactions during VIT are rush and ultra-rush buildup protocols, in which the maintenance dose is reached within a few days. Conventional protocols, which require weeks or months to reach the maintenance phase, seem to be better tolerated.^{3,9} In a systematic literature review, a comparable rate of systemic allergic reactions was found during VIT in aqueous and depot venom allergen extracts in the overall patient population and among patients who underwent vespid VIT. However, a significantly lower frequency of allergic reactions was detected during bee VIT with a depot allergen extract.² Other authors have suggested that these results may be biased due to the slower buildup phase with depot preparations.⁴ In our study, the number of patients with allergic

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2020 The Authors. *Allergy* published by John Wiley & Sons Ltd

TABLE 1 Patient characteristics before venom immunotherapy (VIT) initiation (mean $\pm$ SEM)

	Entire patient cohort		Patients with allergic reactions during VIT	
	Vespid VIT (n = 200)	Bee VIT (n = 20)	Vespid VIT (n = 20)	Bee VIT (n = 4)
Female	117 (59%)	11 (55%)	19 (95%)	2 (50%)
Age (years)	52 (± 1)	49 (± 2)	54 (± 3)	46 (± 5)
Total IgE (kU/L)	206.52 (± 34.46)	204.26 (± 54.77)	355.29 (± 244.36)	397.97 (± 126.26)
Vespid venom-specific IgE (kU/L)	11.85 (± 1.25)	4.33 (± 1.82)	10.62 (± 3.26)	3.29 (± 3.14)
Bee venom-specific IgE (kU/L)	2.14 (± 0.66)	20.96 (± 6.09)	0.20 (± 0.06)	45.73 (± 28.93)
Basal serum tryptase ($\mu\text{g/L}$)	6.33 (± 0.49)	4.33 (± 1.82)	5.02 (± 0.91)	2.89 (± 0.75)
Mueller grade II reaction	38 (19%)	4 (20%)	4 (20%)	0
Mueller grade III reaction	92 (46%)	9 (45%)	9 (45%)	3 (75%)
Mueller grade IV reaction	70 (35%)	7 (35%)	7 (35%)	1 (25%)
Mastocytosis	10 (5%)	1 (5%)	1 (5%)	0
Cardiovascular diseases	48 (24%)	1 (5%)	7 (35%)	0
Allergic asthma	11 (6%)	0	1 (5%)	1 (25%)

**FIGURE 1** Systemic allergic reactions during the up-dosing phase of vespid (A, n = 200) and bee (B, n = 20) venom immunotherapy with an aqueous extract, after the first injection of the depot preparation, and during the maintenance phase, classified according to the World Allergy Organization (WAO) grading system for allergen immunotherapy systemic allergic reactions

reactions was comparable during both the up-dosing and maintenance phases of vespid VIT. In contrast, during bee VIT, we observed that a greater number of patients experienced allergic reactions to the aqueous extract during the up-dosing phase compared to the maintenance phase (after injection of the depot preparation), during which only one patient had an allergic reaction. Similar results have been reported in bee VIT with preparations using a different purification grade.⁵

In conclusion, our data support and supplement previous results⁴⁻⁷ by demonstrating that the likelihood of a systemic allergic reaction after switching from an aqueous to a depot preparation is very low. These data include results from two different preparation manufacturers and with a switch from a standard to a purified extract. Systemic symptoms were rare and led to mild outcomes with primarily cutaneous or gastrointestinal symptoms. Our findings are useful for clinical practice since they indicate that VIT can be continued safely and without complications in an outpatient setting.

KEYWORDS

allergen extract, switch, tolerability, venom immunotherapy

ACKNOWLEDGMENTS

We would like to thank the nursing team of the Division of Allergy and Immunology—Martina Lütticke, Michele Jäckel, and Claudia Tomaschewski—for their support.

CONFLICT OF INTEREST

RS has received a travel grant from ALK-Abelló Arzneimittel GmbH. EO has nothing to disclose. MK has nothing to disclose. MW has received speakers honoraria for advisory boards and lecture activities from Mylan Germany GmbH, ALK-Abelló Arzneimittel GmbH, Allergopharma GmbH & Co. KG, HAL Allergie GmbH, Stallergenes GmbH, Bencard Allergie GmbH, DBV Technologies S.A, Novartis AG, Aimmune Therapeutics UK Limited, Sanofi-Aventis Deutschland GmbH, and Regeneron Pharmaceuticals, Inc.

Roberta Scarpone 
 Elsbeth Oestmann
 Magdalena Kraft 
 Margitta Worm 

Division of Allergy and Immunology, Department of
Dermatology, Venereology and Allergology, Charité –
Universitätsmedizin Berlin, Berlin, Germany

Correspondence

Margitta Worm, Division of Allergy and Immunology,
Department of Dermatology, Venereology and Allergology,
Charité – Universitätsmedizin Berlin, Berlin, Germany.
Email: margitta.worm@charite.de

ORCID

Roberta Scarpone  <https://orcid.org/0000-0001-9959-1944>

Magdalena Kraft  <https://orcid.org/0000-0002-2770-9947>

Margitta Worm  <https://orcid.org/0000-0002-3449-1245>

REFERENCES

1. Sturm GJ, Varga EM, Roberts G, et al. EAACI guidelines on allergen immunotherapy: hymenoptera venom allergy. *Allergy*. 2018;73(4):744-764.
2. Incorvaia C, Frati F, Dell'Albani I, et al. Safety of hymenoptera venom immunotherapy: a systematic review. *Expert Opin Pharmacother*. 2011;12(16):2527-2532. <https://doi.org/10.1517/14656566.2011.616494>.
3. Rueff F, Przybilla B, Bilo MB, et al. Predictors of side effects during the buildup phase of venom immunotherapy for hymenoptera venom allergy: the importance of baseline serum tryptase. *J Allergy Clin Immunol*. 2010;126(1):105-111.e5.
4. Rueff F, Wolf H, Schnitker J, Ring J, Przybilla B. Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations. *Allergy*. 2004;59(6):589-595.
5. Bilo MB, Cinti B, Brianzoni MF, Braschi MC, Bonifazi M, Antonicelli L. Honeybee venom immunotherapy: a comparative study using purified and nonpurified aqueous extracts in patients with normal Basal serum tryptase concentrations. *J Allergy (Cairo)*. 2012; 2012, 1-6.
6. Stoevesandt J, Trautmann A. Lessons from times of shortage: interchangeability of venom preparations and dosing protocols. *Allergy*. 2019;74(7):1392-1395.
7. Worm M. Verträglichkeit der spezifischen immuntherapie während der Umstellung von lyophilisiertem Wespengift auf ein Depotpräparat. *Allergologie*. 2009;32:143-145.
8. Lee H, Roediger C, Bauer A, Zuberbier T, Worm M. Prospective safety analysis of an ultrarush specific immunotherapy in adults with wasp venom allergy. *Allergy*. 2006;61(10):1237-1238.
9. Mosbech H, Muller U. Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European academy of allergology and clinical immunology. *Allergy*. 2000;55(11):1005-1010.